<!DOCTYPE html>
<html lang="de">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hepatorenale Tyrosin√§mie - Teil 1</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        :root {
            --primary-color: #667eea;
            --secondary-color: #764ba2;
            --accent-color: #f093fb;
            --success-color: #4facfe;
            --warning-color: #fa709a;
            --danger-color: #ff6b6b;
            --info-color: #74b9ff;
            --text-primary: #2d3748;
            --text-secondary: #4a5568;
            --text-muted: #718096;
            --bg-white: #ffffff;
            --bg-light: #f8fafc;
            --bg-lighter: #f1f5f9;
            --border-radius: 16px;
            --border-radius-lg: 24px;
            --spacing-xs: 8px;
            --spacing-sm: 16px;
            --spacing-md: 24px;
            --spacing-lg: 32px;
            --spacing-xl: 48px;
            --shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
            --shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
            --shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
        }

        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
            min-height: 100vh;
        }

        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: var(--spacing-md);
        }

        /* Header */
        .header {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
        }

        .header h1 {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color), var(--accent-color));
            background-size: 200% 200%;
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: clamp(2rem, 5vw, 3.5rem);
            font-weight: 700;
            margin-bottom: var(--spacing-sm);
            animation: gradientShift 4s ease-in-out infinite;
        }

        @keyframes gradientShift {
            0%, 100% { background-position: 0% 50%; }
            50% { background-position: 100% 50%; }
        }

        .header p {
            color: var(--text-secondary);
            font-size: 1.3rem;
            font-weight: 400;
        }

        /* Progress bar */
        .progress-container {
            background: #e2e8f0;
            border-radius: 10px;
            height: 8px;
            margin: var(--spacing-lg) auto 0;
            max-width: 400px;
            overflow: hidden;
        }

        .progress-fill {
            height: 100%;
            background: linear-gradient(135deg, var(--primary-color), var(--accent-color));
            border-radius: 10px;
            transition: width 1s ease-out;
            width: 0%;
        }

        /* Part info */
        .part-info {
            background: linear-gradient(135deg, #eff6ff, #dbeafe);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-sm);
        }

        .part-info h3 {
            color: var(--info-color);
            margin-bottom: var(--spacing-sm);
        }

        .part-info p {
            color: var(--text-secondary);
        }

        /* Navigation */
        .navigation {
            display: flex;
            gap: var(--spacing-sm);
            margin-bottom: var(--spacing-lg);
            flex-wrap: wrap;
            justify-content: center;
        }

        .nav-btn {
            background: var(--bg-white);
            border: 2px solid #e2e8f0;
            border-radius: var(--border-radius);
            padding: var(--spacing-md) var(--spacing-lg);
            font-size: 1rem;
            font-weight: 500;
            color: var(--text-secondary);
            cursor: pointer;
            transition: all 0.3s ease;
            text-decoration: none;
            display: block;
            text-align: center;
            box-shadow: var(--shadow-sm);
        }

        .nav-btn:hover {
            transform: translateY(-2px);
            border-color: var(--primary-color);
            color: var(--primary-color);
            box-shadow: var(--shadow-md);
        }

        .nav-btn.active {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border-color: transparent;
        }

        /* Content sections */
        .content-section {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
            display: none;
            animation: fadeIn 0.6s ease-out;
        }

        .content-section.active {
            display: block;
        }

        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(20px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .section-title {
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: var(--spacing-lg);
            position: relative;
            padding-bottom: var(--spacing-sm);
        }

        .section-title::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 4px;
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            border-radius: 2px;
            animation: expandWidth 0.8s ease-out 0.3s both;
        }

        @keyframes expandWidth {
            from { width: 0; }
            to { width: 60px; }
        }

        /* Subsections */
        .subsection {
            margin-bottom: var(--spacing-lg);
            padding: var(--spacing-lg);
            background: var(--bg-light);
            border-radius: var(--border-radius);
            border: 1px solid #e2e8f0;
            transition: all 0.3s ease;
            animation: fadeInStagger 0.6s ease-out both;
        }

        .subsection:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
        }

        .subsection h3 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.5rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }

        .subsection h3::before {
            content: '';
            width: 4px;
            height: 24px;
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
            border-radius: 2px;
        }

        .subsection p {
            color: var(--text-secondary);
            margin-bottom: 1rem;
            line-height: 1.7;
        }

        .subsection ul {
            color: var(--text-secondary);
            padding-left: 1.5rem;
        }

        .subsection li {
            margin-bottom: 0.5rem;
        }

        @keyframes fadeInStagger {
            from { opacity: 0; transform: translateY(20px); }
            to { opacity: 1; transform: translateY(0); }
        }

        .subsection:nth-child(1) { animation-delay: 0.1s; }
        .subsection:nth-child(2) { animation-delay: 0.2s; }
        .subsection:nth-child(3) { animation-delay: 0.3s; }
        .subsection:nth-child(4) { animation-delay: 0.4s; }
        .subsection:nth-child(5) { animation-delay: 0.5s; }

        /* Highlight boxes */
        .highlight-box {
            background: linear-gradient(135deg, #fff7ed, #fed7aa);
            border: 2px solid var(--warning-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            position: relative;
            box-shadow: var(--shadow-sm);
        }

        .highlight-box::before {
            content: 'üí°';
            position: absolute;
            top: -12px;
            left: 24px;
            background: var(--bg-white);
            padding: 0 8px;
            font-size: 1.2rem;
        }

        .highlight-box h4 {
            color: var(--warning-color);
            margin-bottom: var(--spacing-sm);
            font-weight: 600;
        }

        /* Pathway diagram */
        .pathway-diagram {
            background: var(--bg-lighter);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            border: 1px solid #e2e8f0;
        }

        .pathway-diagram h4 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            text-align: center;
            font-weight: 600;
        }

        .enzyme-box {
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
            color: white;
            padding: var(--spacing-sm) var(--spacing-md);
            border-radius: var(--border-radius);
            font-weight: 600;
            text-align: center;
            display: inline-block;
            margin: var(--spacing-xs);
            box-shadow: var(--shadow-sm);
            transition: transform 0.3s ease;
        }

        .enzyme-box:hover {
            transform: scale(1.05);
        }

        .metabolite-box {
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            color: white;
            padding: var(--spacing-sm);
            border-radius: var(--border-radius);
            font-size: 0.9rem;
            text-align: center;
            display: inline-block;
            margin: var(--spacing-xs);
            box-shadow: var(--shadow-sm);
        }

        /* Tables */
        .clinical-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: var(--spacing-md) 0;
            background: var(--bg-white);
            border-radius: var(--border-radius);
            overflow: hidden;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }

        .clinical-table th {
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            color: white;
            padding: var(--spacing-md);
            text-align: left;
            font-weight: 600;
            font-size: 0.95rem;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        .clinical-table td {
            padding: var(--spacing-md);
            border-bottom: 1px solid #f1f5f9;
            transition: all 0.3s ease;
            color: var(--text-primary);
        }

        .clinical-table tbody tr:hover {
            background: #f8fafc;
        }

        .clinical-table tbody tr:last-child td {
            border-bottom: none;
        }

        /* Next button */
        .next-section {
            text-align: center;
            margin-top: var(--spacing-xl);
            padding: var(--spacing-lg);
        }

        .next-btn {
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
            color: white;
            border: none;
            padding: var(--spacing-md) var(--spacing-xl);
            border-radius: var(--border-radius);
            font-size: 1.1rem;
            font-weight: 600;
            cursor: pointer;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            box-shadow: var(--shadow-md);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        .next-btn:hover {
            transform: translateY(-4px) scale(1.05);
            box-shadow: var(--shadow-lg);
        }

        /* Responsive design */
        @media (max-width: 768px) {
            .container {
                padding: var(--spacing-sm);
            }

            .header h1 {
                font-size: 2.5rem;
            }

            .header p {
                font-size: 1.1rem;
            }

            .navigation {
                flex-direction: column;
            }

            .nav-btn {
                width: 100%;
                text-align: center;
            }

            .content-section {
                padding: var(--spacing-md);
            }

            .section-title {
                font-size: 2rem;
            }

            .subsection {
                padding: var(--spacing-md);
            }
        }

        @media (max-width: 480px) {
            .header {
                padding: var(--spacing-md);
            }

            .header h1 {
                font-size: 2rem;
            }

            .section-title {
                font-size: 1.8rem;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>üß¨ Hepatorenale Tyrosin√§mie</h1>
            <p>Teil 1: Grundlagen & Pathophysiologie</p>
            <div class="progress-container">
                <div class="progress-fill" id="progressBar" style="width: 0%"></div>
            </div>
        </div>

        <div class="part-info">
            <h3>üìö Lerneinheit Teil 1</h3>
            <p>Dieser erste Teil behandelt Definition, Epidemiologie, Pathophysiologie und klinische Manifestationen der hepatorenalen Tyrosin√§mie (HT1).</p>
        </div>

        <div class="navigation">
            <button class="nav-btn active" onclick="showSection('definition')">1. Definition</button>
            <button class="nav-btn" onclick="showSection('epidemiologie')">2. Epidemiologie</button>
            <button class="nav-btn" onclick="showSection('pathophysiologie')">3. Pathophysiologie</button>
            <button class="nav-btn" onclick="showSection('klinik')">4. Klinische Manifestationen</button>
        </div>

        <!-- Definition Section -->
        <div class="content-section active" id="definition">
            <h2 class="section-title">Definition & Grundlagen</h2>
            
            <div class="subsection">
                <h3>Was ist hepatorenale Tyrosin√§mie Typ 1?</h3>
                <p>Die <strong>hepatorenale Tyrosin√§mie Typ 1 (HT1)</strong> ist eine seltene, autosomal-rezessiv vererbte Stoffwechselerkrankung im Tyrosinabbau.</p>
                
                <div class="highlight-box">
                    <h4>üéØ Schl√ºsselmerkmale</h4>
                    <p><strong>OMIM:</strong> 276700 | <strong>Orpha Code:</strong> 882</p>
                    <p><strong>Defektes Enzym:</strong> Fumarylazetoazetase/Fumarylazetoazetathydratase (FAH)</p>
                    <p><strong>Chromosom:</strong> 15q25.1 | <strong>Gen:</strong> FAH (MIM 613871)</p>
                    <p><strong>Enzym-Klassifikation:</strong> E.C. 3.7.1.2</p>
                </div>

                <p>HT1 ist die schwerste Form der Tyrosin√§mien und war bis zur Einf√ºhrung von Nitisinon (NTBC) in den 1990er Jahren mit einer sehr schlechten Prognose verbunden.</p>
            </div>

            <div class="subsection">
                <h3>Historischer Kontext</h3>
                <p>Bis Anfang der 1990er Jahre gab es keine kausale Therapie f√ºr HT1. Die betroffenen Kinder hatten eine deutlich eingeschr√§nkte Lebenserwartung, und die einzige Option war eine Lebertransplantation.</p>
                
                <div class="pathway-diagram">
                    <h4>üèõÔ∏è Meilensteine der HT1-Therapie</h4>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin: 15px 0;">
                        <div style="text-align: center;">
                            <div class="enzyme-box" style="background: linear-gradient(135deg, #6b7280, #4b5563);">Vor 1990</div>
                            <p style="margin: 10px 0; font-size: 0.9em;">Nur symptomatische Therapie<br>Lebertransplantation als einzige Option</p>
                        </div>
                        <div style="text-align: center;">
                            <div class="enzyme-box" style="background: linear-gradient(135deg, #f97316, #ea580c);">1990er</div>
                            <p style="margin: 10px 0; font-size: 0.9em;">Entdeckung von Nitisinon<br>Compassionate use</p>
                        </div>
                        <div style="text-align: center;">
                            <div class="enzyme-box">2005</div>
                            <p style="margin: 10px 0; font-size: 0.9em;">EMA-Zulassung als Orphan Drug<br>OPAL-Studie</p>
                        </div>
                        <div style="text-align: center;">
                            <div class="enzyme-box" style="background: linear-gradient(135deg, #22c55e, #16a34a);">Heute</div>
                            <p style="margin: 10px 0; font-size: 0.9em;">Etablierte Therapie<br>Deutlich verbesserte Prognose</p>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Tyrosin√§mie-Klassifikation</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Typ</th>
                            <th>Defektes Enzym</th>
                            <th>Hauptorgane</th>
                            <th>Prognose</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Typ 1 (HT1)</strong></td>
                            <td>Fumarylazetoazetase (FAH)</td>
                            <td>Leber, Niere</td>
                            <td>Schwer, aber therapierbar</td>
                        </tr>
                        <tr>
                            <td><strong>Typ 2</strong></td>
                            <td>Tyrosin-Aminotransferase</td>
                            <td>Augen, Haut, ZNS</td>
                            <td>Mild bis moderat</td>
                        </tr>
                        <tr>
                            <td><strong>Typ 3</strong></td>
                            <td>4-Hydroxyphenylpyruvat-Dioxygenase</td>
                            <td>ZNS</td>
                            <td>Sehr selten, mild</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Epidemiologie Section -->
        <div class="content-section" id="epidemiologie">
            <h2 class="section-title">Epidemiologie</h2>
            
            <div class="subsection">
                <h3>H√§ufigkeit & Verteilung</h3>
                <p>HT1 ist eine sehr seltene Erkrankung mit ausgepr√§gten regionalen Unterschieden in der Pr√§valenz.</p>
                
                <div class="pathway-diagram">
                    <h4>üåç Weltweite Inzidenz</h4>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); gap: 20px; margin: 20px 0;">
                        <div style="text-align: center;">
                            <div class="metabolite-box">Weltweit</div>
                            <p style="margin: 10px 0;">1:100.000 - 1:120.000</p>
                        </div>
                        <div style="text-align: center;">
                            <div class="metabolite-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">Quebec (Saguenay)</div>
                            <p style="margin: 10px 0;">1:1.846<br>(Founder-Effekt)</p>
                        </div>
                        <div style="text-align: center;">
                            <div class="metabolite-box" style="background: linear-gradient(135deg, #f97316, #ea580c);">Finnland</div>
                            <p style="margin: 10px 0;">1:60.000</p>
                        </div>
                        <div style="text-align: center;">
                            <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed);">Deutschland</div>
                            <p style="margin: 10px 0;">1:134.000</p>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Genetische Faktoren</h3>
                <p>Die regionalen H√§ufigkeitsunterschiede sind durch verschiedene Founder-Effekte und Gr√ºnderpopulationen bedingt.</p>
                
                <div class="highlight-box">
                    <h4>üß¨ Wichtige Populationsgenetik</h4>
                    <ul>
                        <li><strong>Quebec (Saguenay-Lac-Saint-Jean):</strong> Mutation IVS12+5G>A (c.1062+5G>A)</li>
                        <li><strong>Finnland:</strong> Verschiedene Mutationen, erh√∂hte Konsanguinit√§t</li>
                        <li><strong>T√ºrkei:</strong> Hohe Rate durch Verwandtenehen</li>
                        <li><strong>Europa:</strong> √úber 80 verschiedene Mutationen beschrieben</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Neugeborenenscreening</h3>
                <p>Seit der Einf√ºhrung des erweiterten Neugeborenenscreenings werden mehr F√§lle fr√ºh erkannt.</p>
                
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Region</th>
                            <th>Screening seit</th>
                            <th>Screeningparameter</th>
                            <th>Detektionsrate</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Deutschland</td>
                            <td>2005</td>
                            <td>Sukzinylazeton (SA)</td>
                            <td>>95%</td>
                        </tr>
                        <tr>
                            <td>USA</td>
                            <td>Variable</td>
                            <td>SA + Tyrosin</td>
                            <td>>90%</td>
                        </tr>
                        <tr>
                            <td>Kanada</td>
                            <td>1970er</td>
                            <td>SA</td>
                            <td>>95%</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Pathophysiologie Section -->
        <div class="content-section" id="pathophysiologie">
            <h2 class="section-title">Pathophysiologie</h2>
            
            <div class="subsection">
                <h3>Tyrosin-Abbauweg</h3>
                <p>HT1 entsteht durch einen Defekt der Fumarylazetoazetase (FAH), dem letzten Enzym im Tyrosinabbauweg.</p>
                
                <div class="pathway-diagram">
                    <h4>üî¨ Metabolischer Abbauweg</h4>
                    <div style="text-align: center; margin: 20px 0;">
                        <div style="display: inline-block; margin: 10px;">
                            <div class="metabolite-box">Tyrosin</div>
                            <div style="margin: 5px 0;">‚Üì</div>
                            <div style="font-size: 0.8em;">Tyrosin-Aminotransferase</div>
                        </div>
                        <br>
                        <div style="display: inline-block; margin: 10px;">
                            <div class="metabolite-box">4-Hydroxyphenylpyruvat</div>
                            <div style="margin: 5px 0;">‚Üì</div>
                            <div style="font-size: 0.8em;">4-Hydroxyphenylpyruvat-Dioxygenase</div>
                            <div style="color: #f97316; font-weight: bold; margin: 5px 0;">‚Üê NTBC hemmt hier</div>
                        </div>
                        <br>
                        <div style="display: inline-block; margin: 10px;">
                            <div class="metabolite-box">Homogentisat</div>
                            <div style="margin: 5px 0;">‚Üì</div>
                            <div style="font-size: 0.8em;">Homogentisat-Dioxygenase</div>
                        </div>
                        <br>
                        <div style="display: inline-block; margin: 10px;">
                            <div class="metabolite-box">Maleylacetoacetat</div>
                            <div style="margin: 5px 0;">‚Üì</div>
                            <div style="font-size: 0.8em;">Maleylacetoacetat-Isomerase</div>
                        </div>
                        <br>
                        <div style="display: inline-block; margin: 10px;">
                            <div class="metabolite-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">Fumarylacetoacetat</div>
                            <div style="margin: 5px 0;">‚Üì</div>
                            <div style="font-size: 0.8em; color: #dc2626; font-weight: bold;">FAH (DEFEKT!)</div>
                        </div>
                        <br>
                        <div style="display: inline-block; margin: 10px;">
                            <div class="metabolite-box">Fumarat + Acetoacetat</div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Toxische Metabolite</h3>
                <p>Durch den FAH-Defekt akkumulieren toxische Metabolite, die die charakteristischen Organsch√§den verursachen.</p>
                
                <div class="highlight-box">
                    <h4>‚ò†Ô∏è Haupttoxine bei HT1</h4>
                    <p><strong>Sukzinylazeton (SA):</strong> Biomarker und Nephrotoxin</p>
                    <p><strong>Fumarylacetoacetat:</strong> Hepatotoxin, DNA-alkylierend</p>
                    <p><strong>Maleylacetoacetat:</strong> Hepatotoxin</p>
                    <p><strong>Œ¥-Aminol√§vulins√§ure:</strong> Neurotoxin (Porphyrie-√§hnlich)</p>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Metabolit</th>
                            <th>Entstehung</th>
                            <th>Toxizit√§t</th>
                            <th>Klinische Bedeutung</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Sukzinylazeton</strong></td>
                            <td>Spontane Zyklisierung</td>
                            <td>Niere (tubul√§rer Schaden)</td>
                            <td>Biomarker, Screening</td>
                        </tr>
                        <tr>
                            <td><strong>Fumarylacetoacetat</strong></td>
                            <td>Direkter Substrataufstau</td>
                            <td>Leber (DNA-Alkylierung)</td>
                            <td>Karzinogenese, Zirrhose</td>
                        </tr>
                        <tr>
                            <td><strong>Œ¥-Aminol√§vulins√§ure</strong></td>
                            <td>H√§m-Synthese-Hemmung</td>
                            <td>Nervensystem</td>
                            <td>Porphyrie-Krisen</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Pathomechanismen</h3>
                <div class="pathway-diagram">
                    <h4>üéØ Organtoxizit√§t</h4>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin: 15px 0;">
                        <div style="text-align: center; padding: 15px; background: #fef2f2; border-radius: 8px; border: 1px solid #fecaca;">
                            <div class="enzyme-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">ü´Ä Leber</div>
                            <p style="font-size: 0.9em; margin: 10px 0;">DNA-Alkylierung<br>‚Üí Mutationen<br>‚Üí HCC-Risiko</p>
                        </div>
                        <div style="text-align: center; padding: 15px; background: #f0f9ff; border-radius: 8px; border: 1px solid #bae6fd;">
                            <div class="enzyme-box" style="background: linear-gradient(135deg, #3b82f6, #2563eb);">ü´ò Niere</div>
                            <p style="font-size: 0.9em; margin: 10px 0;">Tubul√§re Toxizit√§t<br>‚Üí Rachitis<br>‚Üí Azidose</p>
                        </div>
                        <div style="text-align: center; padding: 15px; background: #f5f3ff; border-radius: 8px; border: 1px solid #d8b4fe;">
                            <div class="enzyme-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed);">üß† Nervensystem</div>
                            <p style="font-size: 0.9em; margin: 10px 0;">ALA-Akkumulation<br>‚Üí Neuropathie<br>‚Üí Krisen</p>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <!-- Klinik Section -->
        <div class="content-section" id="klinik">
            <h2 class="section-title">Klinische Manifestationen</h2>
            
            <div class="subsection">
                <h3>Verlaufsformen nach Manifestationsalter</h3>
                <p>HT1 zeigt ein ph√§notypisches Kontinuum, wobei der Schweregrad mit der FAH-Restaktivit√§t korreliert.</p>
                
                <div class="pathway-diagram">
                    <h4>üìä Altersabh√§ngige Symptome</h4>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin: 20px 0;">
                        <div style="background: linear-gradient(135deg, #fef2f2, #fecaca); padding: 15px; border-radius: 8px; border: 2px solid #ef4444;">
                            <h5 style="color: #dc2626; margin-bottom: 10px;">üë∂ Akute Form (0-2 Monate)</h5>
                            <ul style="font-size: 0.9em; color: #dc2626;">
                                <li>Hepatomegalie + Leberfunktionsst√∂rung</li>
                                <li>Akutes Leberversagen m√∂glich</li>
                                <li>Schwere Gedeihst√∂rung</li>
                                <li>Hohe Mortalit√§t unbehandelt</li>
                            </ul>
                        </div>
                        <div style="background: linear-gradient(135deg, #fff7ed, #fed7aa); padding: 15px; border-radius: 8px; border: 2px solid #f97316;">
                            <h5 style="color: #ea580c; margin-bottom: 10px;">üçº Subakute Form (2-12 Monate)</h5>
                            <ul style="font-size: 0.9em; color: #ea580c;">
                                <li>Hepatomegalie</li>
                                <li>Gedeihst√∂rung</li>
                                <li>Rachitis (Vitamin D-resistent)</li>
                                <li>Renale Tubulopathie</li>
                            </ul>
                        </div>
                        <div style="background: linear-gradient(135deg, #f0fdf4, #dcfce7); padding: 15px; border-radius: 8px; border: 2px solid #22c55e;">
                            <h5 style="color: #16a34a; margin-bottom: 10px;">üßí Chronische Form (>12 Monate)</h5>
                            <ul style="font-size: 0.9em; color: #16a34a;">
                                <li>Leberzirrhose</li>
                                <li>Renale Tubulusfunktionsst√∂rung</li>
                                <li>Gedeihst√∂rung</li>
                                <li>Sp√§tkomplikationen: HCC, neurolog. Defizite</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Kardinalsymptome</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Organsystem</th>
                            <th>Symptome</th>
                            <th>Pathomechanismus</th>
                            <th>H√§ufigkeit</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Leber</strong></td>
                            <td>Hepatomegalie, Ikterus, Gerinnungsst√∂rung, Hypoglyk√§mie</td>
                            <td>Hepatozytentoxizit√§t</td>
                            <td>100%</td>
                        </tr>
                        <tr>
                            <td><strong>Niere</strong></td>
                            <td>Tubulopathie, Rachitis, Proteinurie, Kleinwuchs</td>
                            <td>Tubul√§re Toxizit√§t</td>
                            <td>80-90%</td>
                        </tr>
                        <tr>
                            <td><strong>Nervensystem</strong></td>
                            <td>Porphyrie-Krisen, Neuropathie, Dys√§sthesien</td>
                            <td>Œ¥-ALA-Akkumulation</td>
                            <td>15-20%</td>
                        </tr>
                        <tr>
                            <td><strong>Wachstum</strong></td>
                            <td>Gedeihst√∂rung, Kleinwuchs</td>
                            <td>Multifaktoriell</td>
                            <td>70-80%</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Porphyrie-√§hnliche Krisen</h3>
                <p>Ein charakteristisches Merkmal von HT1 sind akute neurologische Krisen, die der akuten intermittierenden Porphyrie √§hneln.</p>
                
                <div class="highlight-box">
                    <h4>‚ö° Klinische Zeichen der Porphyrie-Krisen</h4>
                    <ul>
                        <li><strong>Neurologie:</strong> Periphere Neuropathie, L√§hmungen, Par√§sthesien</li>
                        <li><strong>Vegetativ:</strong> Bauchschmerzen, Erbrechen, Obstipation</li>
                        <li><strong>Psychiatrisch:</strong> Verwirrtheit, Halluzinationen, Agitation</li>
                        <li><strong>Labor:</strong> Erh√∂hte Œ¥-Aminol√§vulins√§ure im Urin</li>
                        <li><strong>Ausl√∂ser:</strong> Infekte, Medikamente, Fasten, Stress</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Langzeitkomplikationen</h3>
                <div class="pathway-diagram">
                    <h4>‚ö†Ô∏è Sp√§tkomplikationen bei unbehandelter HT1</h4>
                    <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
                        <div>
                            <h5 style="color: #dc2626; margin-bottom: 10px;">üéØ Hepatozellul√§res Karzinom (HCC)</h5>
                            <ul style="font-size: 0.9em;">
                                <li>Risiko: >90% bis zum 16. Lebensjahr</li>
                                <li>Fr√ºhe Entstehung m√∂glich (ab 1. Lebensjahr)</li>
                                <li>Multiple Herde h√§ufig</li>
                                <li>Therapie: Lebertransplantation</li>
                            </ul>
                        </div>
                        <div>
                            <h5 style="color: #2563eb; margin-bottom: 10px;">üß† Neurokognitive Defizite</h5>
                            <ul style="font-size: 0.9em;">
                                <li>Aufmerksamkeitsdefizite</li>
                                <li>Exekutive Funktionsst√∂rungen</li>
                                <li>Visuell-r√§umliche Probleme</li>
                                <li>H√§ufiger bei sp√§ter Diagnose</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div class="next-section">
            <p style="margin-bottom: 16px; color: var(--text-muted);">Sie haben Teil 1 abgeschlossen! Fahren Sie mit Teil 2 fort f√ºr Diagnostik, Therapie und Monitoring.</p>
            <button class="next-btn" onclick="alert('Teil 2 wird als n√§chstes erstellt: Diagnostik, Therapie und Monitoring')">
                ‚û°Ô∏è Weiter zu Teil 2
            </button>
        </div>
    </div>

    <script>
        let currentProgress = 0;
        const totalSections = 4;
        
        function showSection(sectionName) {
            // Hide all sections
            const sections = document.querySelectorAll('.content-section');
            sections.forEach(section => {
                section.classList.remove('active');
            });
            
            // Remove active class from all nav buttons
            const navButtons = document.querySelectorAll('.nav-btn');
            navButtons.forEach(btn => {
                btn.classList.remove('active');
            });
            
            // Show selected section
            document.getElementById(sectionName).classList.add('active');
            
            // Update navigation
            event.target.classList.add('active');
            
            // Update progress
            const sectionOrder = ['definition', 'epidemiologie', 'pathophysiologie', 'klinik'];
            currentProgress = (sectionOrder.indexOf(sectionName) + 1) / totalSections * 100;
            document.getElementById('progressBar').style.width = currentProgress + '%';
            
            // Trigger animations
            setTimeout(() => {
                const activeSection = document.querySelector('.content-section.active');
                const subsections = activeSection.querySelectorAll('.subsection');
                subsections.forEach((subsection, index) => {
                    subsection.style.animationDelay = (index * 0.1) + 's';
                });
            }, 100);
        }

        // Initialize progress
        document.addEventListener('DOMContentLoaded', function() {
            showSection('definition');
        });

        // Add keyboard navigation
        document.addEventListener('keydown', function(e) {
            const sections = ['definition', 'epidemiologie', 'pathophysiologie', 'klinik'];
            const currentIndex = sections.findIndex(section => 
                document.getElementById(section).classList.contains('active')
            );
            
            if (e.key === 'ArrowRight' && currentIndex < sections.length - 1) {
                const nextButton = document.querySelector(`.nav-btn[onclick*="${sections[currentIndex + 1]}"]`);
                nextButton.click();
            } else if (e.key === 'ArrowLeft' && currentIndex > 0) {
                const prevButton = document.querySelector(`.nav-btn[onclick*="${sections[currentIndex - 1]}"]`);
                prevButton.click();
            }
        });
    </script>
</body>
</html>
